Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas

Biochemical Pharmacology

Volumn 72, Issue 10, 2006, Pages 1246-1256

  Faber, Anthony C ^a   Dufort, Fay J ^a   Blair, Derek ^a   Wagner, Dean ^a   Roberts, Mary F ^a   Chiles, Thomas C ^a  

^a BOSTON COLLEGE   (United States)

Author keywords

Cell cycle; Diffuse large B cell lymphoma; Glycolysis; Phosphatidylinositol 3 kinase; Resveratrol

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DEOXYGLUCOSE; GLUCOSE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P70; PROTEIN S6; RESVERATROL; S6 KINASE;

ARTICLE; B CELL LYMPHOMA; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CHEMICAL ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL LINE, TUMOR; CHROMONES; ENZYME INHIBITORS; GLUCOSE; GLYCOLYSIS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, LARGE-CELL, DIFFUSE; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; STILBENES;

EID: 33749991874     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.08.009     Document Type: Article

References (48)

1. Moreno J.J. Resveratrol modulates arachidonic acid release, prostaglandin synthesis, and 3T6 fibroblast growth. J Pharmacol Exp Ther 294 (2000) 333-338
2. Subbaramaiah K., Chung W.J., Michaluart P., Telang N., Tanabe T., Inoue H., et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 273 (1998) 21875-21882
3. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 (1997) 218-220
4. Holmes-McNary M., and Baldwin A.S. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 60 (2000) 3477-3483
5. Manna S.K., Mukhopadhyay A., and Aggarwal B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164 (2000) 6509-6519
6. Fontecave M., Lepoivre M., Elleingand E., Gerez C., and Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett 421 (1998) 277-279
7. Sun N.J., Woo S.H., Cassady J.M., and Snapka R.M. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J Nat Prod 61 (1998) 362-366
8. 2-terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol Carcinogenesis 33 (2002) 244-250
9. She Q.B., Bode A.M., Ma W.Y., Chen N.Y., and Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 MAPK. Cancer Res 61 (2001) 1604-1610
10. Mitchell S.H., Zhu W., and Young C.Y. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 59 (1999) 5892-5895
11. Hsieh T.C., and Wu J.M. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 249 (1999) 109-115
12. Surh Y.J., Hurh Y.J., Kang J.Y., Lee E., Kong G., and Lee S.J. Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett 140 (1999) 1-10
13. Dorrie J., Gerauer H., Wachter Y., and Zunino S.J. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res 61 (2001) 4731-4739
14. Clement M.V., Hirpara J.L., Chawdhury S.H., and Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 92 (1998) 996-1002
15. Ansell S.M., and Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 80 (2005) 1087-1097
16. Abramson J.S., and Shipp M.A. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 106 (2005) 1164-1174
17. Armitage J.O., and Weisenburger D.D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16 (1998) 2780-2795
18. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
19. Shipp M.A., Ross K.N., Tamayo P., Weng A.P., Kutok J.L., Aguiar R.C., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8 (2002) 68-74
20. Davis R.E., Brown K.D., Siebenlist U., and Staudt L.M. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194 (2001) 1861-1874
21. Monti S., Savage K.J., Kutok J.L., Feuerhake F., Kurtin P., Mihm M., et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105 (2005) 1851-1861
22. Rosenwald A., Wright G., Leroy K., Yu X., Gaulard P., Gascoyne R.D., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198 (2003) 851-862
23. Savage K.J., Monti S., Kutok J.L., Cattoretti G., Neuberg D., De Leval L., et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102 (2003) 3871-3879
24. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 15 (2004) 177-182
25. Amaravadi R., and Thompson C.B. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115 (2005) 2618-2624
26. Luo J., Manning B.D., and Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4 (2003) 257-262
27. Stephens L., Anderson K., Stokoe D., Erdjument-Bromage H., Painter G.F., Holmes A.B., et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279 (1998) 710-714
28. Plas D.R., and Thompson C.B. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24 (2005) 7435-7442
29. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64 (2004) 3892-3899
30. Rathmell J.C., Fox C.J., Plas D.R., Hammerman P.S., Cinalli R.M., and Thompson C.B. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 23 (2003) 7315-7328
31. Mehra S., Messner H., Minden M., and Chaganti R.S. Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. Genes Chromosomes Cancer 33 (2003) 225-234
32. Doughty C.A., Bleiman B.F., Wagner D.J., Dufort F.J., Mataraza J.M., Roberts M.F., et al. Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth. Blood 107 (2006) 4458-4465
33. Frauwirth K.A., Riley J.L., Harris M.H., Parry R.V., Rathmell J.C., Plas D.R., et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 16 (2002) 769-777
34. Ciulla R.A., and Roberts M.F. Effects of osmotic stress on Methanococcus thermolithotrophicus: 13C-edited 1H-NMR studies of osmolyte turnover. Biochim Biophys Acta 1427 (1999) 193-204
35. Yang L., Dan H.C., Sun M., Liu Q., Sun X.M., Feldman R.I., et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64 (2004) 4394-4399
36. Rathmell J.C., Vander Heiden M.G., Harris M.H., Frauwirth K.A., and Thompson C.B. In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol Cell 6 (2000) 683-692
37. Shaffer A.L., Rosenwald A.M., Hurt E.M., Giltane J.M., Lam L.T., Pickeral O.K., et al. Signatures of the immune response. Immunity 15 (2001) 375-385
38. Geschwind J.F., Georgiades C.S., Ko Y.H., and Pedersen P.L. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Exp Rev Anticancer Ther 4 (2004) 449-457
39. Su J.L., Lin M.T., Hong C.C., Chang C.C., Shiah S.G., Wu C.W., et al. Resveratrol induces FasL-related apoptosis through Cdc42 activation of ASK1/JNK-dependent signaling pathway in human leukemia HL-60 cells. Carcinogenesis 26 (2005) 1-10
40. Fukuda R., Hayashi A., Utsunomiya A., Nukuda Y., Fukui R., Itoh K., et al. Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL). Proc Natl Acad Sci USA 102 (2005) 15213-15218
41. Tjin E.P., Groen R.W., Vogelzang I., Derksen P.W., Klok M.D., Meijer H.P., et al. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood 107 (2006) 760-768
42. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
43. Speaks S.L., Sanger W.G., Masih A.S., Harrington D.S., Hess M., and Armitage J.O. Recurrent abnormalities of chromosome bands 10q23-25 in non-Hodgkin's lymphoma. Genes Chromosomes Cancer 5 (1992) 239-243
44. Butler M.P., Wang S.I., Chaganti R.S., Parsons R., and Dalla-Favera R. Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas. Genes Chromosomes Cancer 24 (1999) 322-327
45. Warburg O. On the origin of cancer cells. Science 123 (1956) 309-314
46. Mathupala S.P., Rempel A., and Pedersen P.L. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29 (1997) 339-343
47. Engel M., Mazurek S., Eigenbrodt E., and Welter C. Phosphoglycerate mutase-derived polypeptide inhibits glycolytic flux and induces cell growth arrest in tumor cell lines. J Biol Chem 279 (2004) 35803-35812
48. Elstrom R., Guan L., Baker G., Nakhoda K., Vergilio J.A., Zhuang H., et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101 (2003) 3875-3876